Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Plant Allergenic Extract [EPC]
Fuchsia Magellanica Whole is a non-standardized plant allergenic extract used primarily in the diagnosis and treatment of hypersensitivity reactions. It belongs to the class of allergenic extracts utilized in clinical immunology for skin testing and subcutaneous immunotherapy.
Name
Fuchsia Magellanica Whole
Raw Name
FUCHSIA MAGELLANICA WHOLE
Category
Non-Standardized Plant Allergenic Extract [EPC]
Drug Count
4
Variant Count
4
Last Verified
February 17, 2026
About Fuchsia Magellanica Whole
Fuchsia Magellanica Whole is a non-standardized plant allergenic extract used primarily in the diagnosis and treatment of hypersensitivity reactions. It belongs to the class of allergenic extracts utilized in clinical immunology for skin testing and subcutaneous immunotherapy.
Detailed information about Fuchsia Magellanica Whole
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Fuchsia Magellanica Whole.
Fuchsia Magellanica Whole refers to a biological allergenic extract derived from the entire plant structure of Fuchsia magellanica, commonly known as the hardy fuchsia or hummingbird fuchsia. This agent is pharmacologically classified as a Non-Standardized Plant Allergenic Extract [EPC]. In the realm of clinical immunology, it is used as a tool to identify specific IgE-mediated (Immunoglobulin E) sensitivities in patients who exhibit allergic rhinitis (hay fever), conjunctivitis, or allergic asthma when exposed to environmental botanical matter.
Unlike standardized extracts (such as certain grass or dust mite extracts that have measured bioequivalent allergy units), Fuchsia Magellanica Whole is categorized as 'non-standardized.' This means its potency is typically expressed in terms of Weight/Volume (w/v) or Protein Nitrogen Units (PNU) rather than biological activity units. It is primarily indicated for patients who show clinical symptoms of allergy that correlate with the presence of the Fuchsia magellanica plant in their local environment. This plant, native to the lower regions of South America but widely cultivated globally as an ornamental shrub, can produce pollen and organic particulate matter that serves as an inhalant allergen.
Fuchsia Magellanica Whole belongs to a class of drugs called Allergenic Extracts. These are biological substances used for both 'in vivo' (within the living body) diagnostic testing and for 'hyposensitization' (immunotherapy). The FDA approval history for these extracts dates back several decades, often falling under the regulatory framework for biologics. Because these extracts are derived from natural sources, they contain a complex mixture of proteins, glycoproteins, and polysaccharides that constitute the allergenic profile of the plant.
The mechanism of action for Fuchsia Magellanica Whole depends on its clinical application: diagnostic or therapeutic.
When used for diagnostic purposes, such as a skin prick test (SPT) or intradermal test, the extract is introduced into the epidermis or dermis. If the patient is sensitized, specific IgE antibodies bound to the surface of mast cells in the skin will recognize the Fuchsia magellanica antigens. This recognition triggers a cross-linking of IgE receptors, leading to mast cell degranulation. This process releases inflammatory mediators, most notably histamine, leukotrienes, and prostaglandins. The clinical result is a 'wheal and flare' reaction—a raised, itchy bump surrounded by redness—which is measured by the clinician to determine the degree of sensitivity.
When used in subcutaneous immunotherapy (SCIT), the extract is administered in gradually increasing doses. The goal is to induce 'immunological tolerance.' At the molecular level, this involves a shift in the immune response from a Th2-dominated profile (which promotes IgE production and allergic inflammation) to a Th1-dominated or T-regulatory (Treg) profile. This transition leads to the production of 'blocking antibodies,' specifically IgG4. These IgG4 antibodies compete with IgE for the allergen-binding sites, effectively preventing the allergic cascade upon future environmental exposure. Additionally, it reduces the recruitment of eosinophils and basophils to the respiratory mucosa.
As a biological extract administered either epicutaneously (on the skin) or subcutaneously (under the skin), the pharmacokinetic profile of Fuchsia Magellanica Whole differs significantly from traditional synthetic small-molecule drugs.
Fuchsia Magellanica Whole is utilized for the following indications:
Fuchsia Magellanica Whole is available in the following dosage forms:
> Important: Only your healthcare provider can determine if Fuchsia Magellanica Whole is right for your specific condition. Administration must be performed in a clinical setting equipped to handle severe allergic reactions.
Dosage for Fuchsia Magellanica Whole is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity levels. There is no 'standard' dose due to the non-standardized nature of the extract.
Fuchsia Magellanica Whole can be used in children, typically those aged 5 years and older who are able to cooperate with the injection schedule and report symptoms.
No specific dosage adjustments are required for patients with renal impairment, as the clearance of allergenic proteins does not rely on renal filtration. However, the patient's overall health status should be stable before administration.
No dosage adjustments are necessary for hepatic impairment. The metabolism of these biological extracts occurs through proteolytic pathways independent of the liver's cytochrome P450 system.
Elderly patients may be at higher risk for complications if a systemic reaction occurs, particularly if they have underlying cardiovascular disease. Dosing should be approached conservatively, and the clinician must ensure the patient is not taking medications (like beta-blockers) that could complicate the treatment of a reaction.
Fuchsia Magellanica Whole is never self-administered. It must be given by a healthcare professional in a medical office, clinic, or hospital setting.
If a dose of immunotherapy is missed, the schedule must be adjusted.
An overdose in the context of allergenic extracts refers to receiving a dose higher than the patient's current tolerance level.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.
Side effects of Fuchsia Magellanica Whole are common, as the treatment is designed to provoke an immune response. Most reactions are localized to the site of administration.
> Warning: Stop the administration process and call your doctor or emergency services immediately if you experience any of these symptoms after leaving the clinic.
There are no known long-term 'toxic' effects of Fuchsia Magellanica Whole, as it is a biological protein extract. However, long-term immunotherapy can lead to:
While Fuchsia Magellanica Whole may not have a specific individual 'Black Box' label for this exact plant, the class of Allergenic Extracts carries a general warning mandated by the FDA regarding the risk of severe systemic reactions.
Summary of Warning: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. They should only be administered by physicians who are exceptionally experienced in the treatment of allergic diseases and the management of systemic reactions. Patients with unstable or steroid-dependent asthma are at increased risk. Epinephrine must be available for immediate use.
Report any unusual symptoms to your healthcare provider, even if they seem minor at first. Early intervention is key to managing allergic reactions.
Fuchsia Magellanica Whole is a potent biological agent. Its use is restricted to diagnostic and therapeutic protocols managed by specialists. Patients must be aware that the very substance used to treat their allergy can, in certain circumstances, trigger a severe allergic episode. Safety depends on strict adherence to observation periods and honest reporting of all symptoms to the medical staff.
No specific FDA black box warning exists for Fuchsia Magellanica Whole as a standalone entity, but it falls under the mandatory class warning for all allergenic extracts. This warning emphasizes that these products can cause anaphylaxis and must be administered in a setting where emergency resuscitative equipment and personnel are immediately available. The warning also highlights that patients with high levels of sensitivity or those undergoing rapid 'rush' immunotherapy are at an elevated risk.
Fuchsia Magellanica Whole does not typically cause sedation. However, if a patient experiences a systemic reaction or receives treatment for one (such as diphenhydramine/Benadryl), they may become drowsy. It is generally safe to drive after the 30-minute observation period provided the patient feels entirely well and has had no reaction.
There is no direct chemical interaction between alcohol and Fuchsia Magellanica Whole. However, alcohol consumption can cause vasodilation (widening of blood vessels), which may theoretically increase the rate of allergen absorption or worsen the symptoms of an allergic reaction. It is advisable to avoid alcohol for several hours before and after an injection.
> Important: Discuss all your medical conditions, including any history of fainting or heart problems, with your healthcare provider before starting Fuchsia Magellanica Whole.
| Interaction Type | Mechanism | Clinical Consequence | Management |
|---|---|---|---|
| Beta-Blockers | Pharmacodynamic (Antagonism of Epinephrine) | Reduced efficacy of rescue meds in anaphylaxis | Switch to alternative antihypertensive if possible |
| Antihistamines | Pharmacodynamic (H1-receptor blockade) | False-negative diagnostic skin tests | Discontinue 72-168 hours before testing |
| ACE Inhibitors | Pharmacodynamic (Bradykinin pathway) | Increased severity of systemic reactions | Monitor closely or evaluate risk/benefit |
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure or heart rhythm.
Fuchsia Magellanica Whole must NEVER be used in the following circumstances:
Conditions requiring careful risk-benefit analysis include:
Patients allergic to Fuchsia magellanica may exhibit cross-reactivity with other members of the Onagraceae (Evening Primrose) family. This includes plants like Oenothera and Epilobium. If a patient has had a severe reaction to any of these related species, Fuchsia Magellanica Whole should be used with extreme caution starting at a much lower concentration.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of autoimmune disease or lung problems, before prescribing Fuchsia Magellanica Whole.
FDA Pregnancy Category C. There are no adequate and well-controlled studies of Fuchsia Magellanica Whole in pregnant women.
It is generally considered safe to continue Fuchsia Magellanica Whole immunotherapy while breastfeeding. The large protein molecules in the extract are unlikely to pass into breast milk in significant quantities, and even if they did, they would likely be digested in the infant's gastrointestinal tract. However, the mother should be monitored for reactions as usual.
Elderly patients (over 65) require careful screening for cardiovascular and pulmonary health.
Renal impairment does not alter the pharmacokinetics of allergenic extracts. However, patients with end-stage renal disease (ESRD) may have altered immune function, which could theoretically affect the efficacy of the desensitization process. No specific GFR-based adjustments are published.
Liver disease does not affect the metabolism of Fuchsia Magellanica Whole. The primary concern in patients with severe hepatic impairment would be their overall physiological stability and ability to recover from a systemic allergic reaction.
> Important: Special populations require individualized medical assessment and may need more frequent monitoring during the build-up phase of treatment.
Fuchsia Magellanica Whole acts as an external antigen that interacts with the adaptive immune system.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous/Epicutaneous) |
| Protein Binding | N/A (Biological Proteins) |
| Half-life | Variable (Proteins degraded over hours to days) |
| Tmax | 15-30 mins (Diagnostic) / Hours (Systemic absorption) |
| Metabolism | Proteolysis (Extracellular and intracellular) |
| Excretion | Cellular turnover/metabolic degradation |
Fuchsia Magellanica Whole is a Non-Standardized Plant Allergenic Extract. It is part of the broader category of 'Biologicals' used in Allergy and Immunology. Related medications include other plant extracts like Oak, Ragweed, and various Grass extracts, though each is specific to its own botanical antigens.
Common questions about Fuchsia Magellanica Whole
Fuchsia Magellanica Whole is primarily used by allergy specialists to diagnose and treat specific allergies to the hardy fuchsia plant. In a diagnostic setting, it is applied to the skin to see if it causes a 'wheal and flare' reaction, indicating an IgE-mediated sensitivity. For treatment, it is used in allergen immunotherapy, commonly known as 'allergy shots.' This involves giving small, increasing doses of the extract over time to help the patient's immune system become less sensitive to the plant. It is specifically intended for patients whose symptoms, such as hay fever or asthma, are triggered by exposure to this specific plant.
The most frequent side effects are localized reactions at the site where the extract was injected or applied. These include redness, itching, and swelling, which can range from a small bump to a larger area of inflammation. Some patients may also experience a temporary increase in their usual allergy symptoms, such as sneezing or watery eyes, shortly after the injection. These local reactions are usually mild and resolve within a day or two. However, any local reaction larger than the palm of your hand should be reported to your doctor, as it may require a dose adjustment.
While there is no direct chemical interaction between alcohol and the allergenic extract, healthcare providers generally recommend avoiding alcohol on the day of your injection. Alcohol can cause blood vessels to dilate, which might speed up the absorption of the allergen into your bloodstream, potentially increasing the risk of a systemic reaction. Additionally, alcohol can mask or mimic some early symptoms of an allergic reaction, such as flushing or a rapid heartbeat, making it harder to identify a serious problem. To ensure maximum safety during your immunotherapy, it is best to remain sober for several hours before and after your appointment.
Fuchsia Magellanica Whole is classified as Pregnancy Category C, meaning its safety has not been fully established in pregnant women. Standard clinical practice is to avoid starting new immunotherapy (the build-up phase) during pregnancy because of the risk of anaphylaxis, which could deprive the fetus of oxygen. However, if a patient is already on a stable maintenance dose and becomes pregnant, many allergists will continue the treatment at that same dose. The decision is highly individualized and depends on the severity of the mother's allergies. You must inform your allergist immediately if you become pregnant or are planning to conceive.
Allergen immunotherapy is a slow process and does not provide immediate relief like an antihistamine or a nasal spray. Most patients enter a 'build-up phase' that lasts 3 to 6 months, during which the dose is gradually increased. Significant improvement in allergy symptoms is typically not noticed until the patient reaches their maintenance dose. For many, it takes 6 to 12 months of consistent treatment to feel a meaningful difference. A full course of treatment usually lasts 3 to 5 years to ensure long-lasting protection even after the injections are stopped.
Yes, you can stop taking Fuchsia Magellanica Whole injections suddenly without experiencing 'withdrawal' symptoms like you might with certain other medications. However, stopping the treatment means you will lose the progress you have made toward becoming desensitized to the allergen. If you stop for several weeks or months and then decide to restart, you cannot go back to your previous high dose. Your doctor will have to restart you at a much lower, safer dose to prevent a severe reaction. It is important to discuss your reasons for wanting to stop with your allergist first.
If you miss an injection, you should contact your allergy clinic as soon as possible to reschedule. The safety of the next dose depends on how much time has passed since your last one. If only a few extra days have passed, your doctor may give you your scheduled dose. If several weeks have passed, your doctor will likely need to reduce the dose to ensure your immune system can still handle it safely. Never try to 'double up' on doses to make up for a missed one, as this significantly increases the risk of a life-threatening allergic reaction.
There is no clinical evidence to suggest that Fuchsia Magellanica Whole or other allergenic extracts cause weight gain. These extracts consist of small amounts of natural proteins and do not contain hormones, steroids, or high-calorie components that typically lead to weight changes. If you experience weight gain while on immunotherapy, it is likely due to other factors such as lifestyle changes, other medications (like oral steroids used for asthma), or an unrelated medical condition. You should discuss any unexpected weight changes with your primary care physician.
Fuchsia Magellanica Whole can be taken alongside most common medications, but there are some critical exceptions. You must tell your doctor if you are taking beta-blockers or ACE inhibitors for blood pressure or heart conditions, as these can make allergic reactions more dangerous and harder to treat. Additionally, you will need to stop taking antihistamines for several days before a skin test, as they can cause a false negative result. Most other daily medications for conditions like cholesterol, diabetes, or birth control do not interact with allergenic extracts.
The concept of 'generic' vs. 'brand name' works differently for allergenic extracts than for pills. Fuchsia Magellanica Whole is a biological product produced by several different specialized laboratories. While the extracts from different companies are similar, they are not considered 'interchangeable' in the same way generic ibuprofen is for Advil. If your clinic switches to an extract from a different manufacturer, your doctor may need to adjust your dose slightly to ensure safety, as the potency of non-standardized extracts can vary between producers.